阿魏酸钠对大鼠肝纤维化的作用

Effects of sodium ferulate on liver fibrosis in experimental cirrhotic rats

目的:探索阿魏酸钠对胆管结扎所致大鼠实验性肝纤维化的作用.方法:用胆管结扎方法制作肝纤维化大鼠模型.将实验大鼠分为3组:对照组、胆管结扎所致肝纤维化模型组、胆管结扎后阿魏酸钠治疗组.检测、比较各组大鼠血清肝功能指标:谷丙转氨酶(alanine transaminase,ALT)、谷草转氨酶(aspartate aminotransferase,AST)、白蛋白(albumin,ALB)、总胆红素(total bilirubin,TBIL)、直接胆红素(direct bilirubin,D B I L)、γ-谷氨酰基转移酶(γ-g l u t a m y l transferase,γ-GGT).称取各组大鼠体质量、肝脏重量并计算肝指数.阿魏酸钠治疗对肝脏纤维化程度的影响通过显微镜下观察肝脏HE染色切片、透射电镜观察肝脏超微结构改变,以及免疫组织化学检测肝脏α-平滑肌肌动蛋白(α-smooth muscle actin,α-SMA)表达积分吸光度值(integrated absorbance,IA)等综合评定.结果:用阿魏酸钠治疗后,肝纤维化大鼠的肝功能较治疗前并无明显改善.模型组大鼠的肝指数较对照组明显增加(7.83%±0.57%vs4.05%±0.17%,P<0.01);治疗组大鼠的肝指数与模型组比较有所减低(7.08%±0.68%vs7.83%±0.57%,P<0.05).病理观察提示,治疗组大鼠肝脏纤维化程度及肝细胞破坏程度较模型组有所减低.免疫组织化学检测提示模型组大鼠肝脏α-SMA表达量均高于对照组(113224.74±45518.79 vs 4197.80±1364.97,P<0.01);经过阿魏酸钠处理后的治疗组大鼠肝脏α-SMA的表达量有所减低(46451.65±15600.56 vs 113224.74±45518.79,P<0.05).结论:阿魏酸钠对胆管结扎所致的实验性肝纤维化大鼠有抗肝纤维化作用.

AIM： To assess the effects of sodium ferulate on liver fibrosis in rats with experimental cirrhosis induced by bile duct Iigation. METHODS： Liver cirrhosis was experimentally induced in rats by bile duct ligation. Rats were divided into three groups： a control group, a model group and a treatment group, which were treated by sham-operation, bile duct ligation, and sodium ferulate injection after bile duct ligation, respectively. Biochemical parameters were measured. Body weight, liver weight and liver index were compared between groups. Pathological characteristics of liver tissues were observed by optical microscopy and transmission electron microscopy, and the integrated absorbance of hepatic α-smooth muscle actin was determined by immunohistochemistry. RESULTS： Biochemical parameters did not differ between the model group and treatment group. Liver index in the model group increased compared with control rats （7.83% ± 0.57% vs 4.05% ± 0.17%, P 〈 0.01）; after treatment, the index decreased significantly （7.08% ± 0.68% vs 7.83% ± 0.57%, P 〈 0.05）. Pathological observation revealed that the degree of fibrosis and severity of hepatocyte damage in the treatment group were lower than those in the model group. Hepatic α-SMA content in the model group was significantly higher than that in the control group （113224.74 ± 45518.79 vs 4197.80 ± 1364.97, P 〈 0.01）. After treatment with sodium ferulate, hepatic α-SMA content decreased in the treatment group compared with the model group （46451.65 ± 15600.56 vs 113224.74 ± 45518.79, P 〈 0.05）. CONCLUSION： Sodium ferulate has a therapeutic effect on liver fibrosis in rats with experimental cirrhosis induced by bile duct ligation.